Research programme: neuropsychiatric disorder therapeutics - Roche/SRI International
Latest Information Update: 16 Jul 2016
At a glance
- Originator Roche; SRI International
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in USA
- 12 Nov 2009 Preclinical trials in Cognition disorders in USA (unspecified route)